Journal of atrial fibrillation最新文献

{"title":"Reversible Mechanical Atrioventricular Block Caused By A Steerable Introducer Sheath During Transseptal Catheterization.","authors":"Gregory P Siroky,&nbsp;Devendra Bisht,&nbsp;Hieu Huynh,&nbsp;Mena Yacoub,&nbsp;Shawn Lee,&nbsp;Seth Keller,&nbsp;Ranjit Suri","doi":"10.4022/jafib.20200469","DOIUrl":"https://doi.org/10.4022/jafib.20200469","url":null,"abstract":"<p><p>A 62-year-old woman presents for pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation. During transseptal catheterization (TSC) the patient sustained mechanical injury to the atrioventricular node (AVN) with consequent complete heart block (CHB). Injury to the AVN and CHB recovered after approximately forty minutes. The patient subsequently underwent a successful PVI with the remainder of the hospital stay uneventful. We present a case of reversible injury to the AVN caused by a steerable introducer sheath during TSC and discuss the mechanisms of injury as well as potential measures to avoid such a complication in the future.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200469"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691279/pdf/jafib-13-20200469.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: the QDOT-MICRO Workflow Sttudy.","authors":"Tom De Potter,&nbsp;Massimo Grimaldi,&nbsp;Henrik Kjaerulf Jensen,&nbsp;Josef Kautzner,&nbsp;Petr Neuzil,&nbsp;Johan Vijgen,&nbsp;Andrea Natale,&nbsp;Steen Buus Kristiansen,&nbsp;Peter Lukac,&nbsp;Petr Peichl,&nbsp;Vivek Y Reddy","doi":"10.4022/jafib.20200460","DOIUrl":"https://doi.org/10.4022/jafib.20200460","url":null,"abstract":"<p><strong>Background: </strong>A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting.</p><p><strong>Methods: </strong>This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey.</p><p><strong>Results: </strong>All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator.</p><p><strong>Conclusions: </strong>Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200460"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691282/pdf/jafib-13-20200460.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Utility of Smartwatch Technology for Atrial Fibrillation Detection - A Systematic Analysis.","authors":"Mehmet Ali Elbey,&nbsp;Daisy Young,&nbsp;Sri Harsha Kanuri,&nbsp;Krishna Akella,&nbsp;Ghulam Murtaza,&nbsp;Jalaj Garg,&nbsp;Donita Atkins,&nbsp;Sudha Bommana,&nbsp;Sharan Sharma,&nbsp;Mohit Turagam,&nbsp;Jayashree Pillarisetti,&nbsp;Peter Park,&nbsp;Rangarao Tummala,&nbsp;Alap Shah,&nbsp;Scott Koerber,&nbsp;Poojita Shivamurthy,&nbsp;Chandrasekhar Vasamreddy,&nbsp;Rakesh Gopinathannair,&nbsp;Dhanunjaya Lakkireddy","doi":"10.4022/jafib.20200446","DOIUrl":"https://doi.org/10.4022/jafib.20200446","url":null,"abstract":"<p><strong>Background: </strong>Smartphone technologies have been recently developed to assess heart rate and rhythm, but their role in accurately detecting atrial fibrillation (AF) remains unknown.</p><p><strong>Objective: </strong>We sought to perform a meta-analysis using prospective studies comparing Smartwatch technology with current monitoring standards for AF detection (ECG, Holter, Patch Monitor, ILR).</p><p><strong>Methods: </strong>We performed a comprehensive literature search for prospective studies comparing Smartwatch technology simultaneously with current monitoring standards (ECG, Holter, and Patch monitor) for AF detection since inception to November 25th, 2019. The outcome studied was the accuracy of AF detection. Accuracy was determined with concomitant usage of ECG monitoring, Holter monitoring, loop recorder, or patch monitoring.</p><p><strong>Results: </strong>A total of 9 observational studies were included comparing smartwatch technology, 3 using single-lead ECG monitoring, and six studies using photoplethysmography with routine AF monitoring strategies. A total of 1559 patients were enrolled (mean age 63.5 years, 39.5% had an AF history). The mean monitoring time was 75.6 days. Smartwatch was non-inferior to composite ECG monitoring strategies (OR 1.06, 95% CI 0.93 - 1.21, p=0.37), composite 12 lead ECG/Holter monitoring (OR 0.90, 95% CI 0.62 - 1.30, p=0.57) and patch monitoring (OR 1.28, 95% CI 0.84 - 1.94, p=0.24) for AF detection. The sensitivity and specificity for AF detection using a smartwatch was 95% and 94%, respectively.</p><p><strong>Conclusions: </strong>Smartwatch based single-lead ECG and photoplethysmography appear to be reasonable alternatives for AF monitoring.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200446"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691284/pdf/jafib-13-20200446.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New-onset Heart Failure With Atrial Fibrillation: A Distinct Type of Cardiomyopathy?","authors":"Vinay Mehta,&nbsp;Alexander Albers,&nbsp;Maharaj Singh,&nbsp;Ana Cristina Perez Moreno,&nbsp;Timothy E Paterick","doi":"10.4022/jafib.20200441","DOIUrl":"https://doi.org/10.4022/jafib.20200441","url":null,"abstract":"<p><strong>Objective: </strong>There is limited research comparing demographic and clinical characteristics between patients who present with atrial fibrillation (AF) and new-onset cardiomyopathy (CM) to patients with new-onset CM without dysrhythmia. We aimed to evaluate clinical characteristics and outcomes in patients with new-onset CM with and without AF and to report their real-world treatment.</p><p><strong>Methods and results: </strong>The study population was identified using patient records from our healthcare system from January 1, 2012 to September 30, 2016. Patients with a left ventricular ejection fraction ≤40% without a prior history of CM were divided into two groups; those with an antecedent or concomitant diagnosis of AF (AF-CM group) and those with no history of dysrhythmia (CM group). Patients in the AF-CM group (n=196) were older, more likely to be male, had a higher burden of comorbidities but lower levels of cardiac biomarkers, and had lower voltage on surface electrocardiogram than the CM group (n=197). In AF-CM, symptom onset was insidious, leading to a higher likelihood of outpatient diagnosis; 88.3% of AF-CM patients presented with atypical symptoms of AF. The AF-CM group had higher mortality on follow-up. Only 8.7% of patients in this group underwent an ablation procedure. Women, those with a history of coronary artery disease, and older patients were less likely to receive a cardioversion or ablation procedure.</p><p><strong>Conclusions: </strong>Patients presenting with new-onset CM associated with AF have a markedly different risk factor and demographic profile, clinical presentation, and outcomes. In real-world practice, a minority of patients undergo a rhythm control strategy.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200441"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691286/pdf/jafib-13-20200441.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Atrial Fibrillation Ablation in the Young - A Real World Analysis.","authors":"Naga Venkata K Pothineni,&nbsp;Dinesh Voruganti,&nbsp;Kanishk Agnihotri,&nbsp;Rakesh Gopinathannair,&nbsp;Dhanunjaya Lakkireddy,&nbsp;Pasquale Santangeli","doi":"10.4022/jafib.20200489","DOIUrl":"https://doi.org/10.4022/jafib.20200489","url":null,"abstract":"Corresponding Author Naga Venkata K Pothineni, MD Division of Cardiovascular Medicine, University of Pennsylvania 9 Founders, 3400 Spruce street, Philadelphia, PA, USA","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200489"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691278/pdf/jafib-13-20200489.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39871665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemodynamic Management of Patients with Ejection Fraction < 50% Undergoing Pulmonary Vein Ablation.","authors":"Aaron B Hesselson,&nbsp;Heather Hesselson","doi":"10.4022/jafib.20200439","DOIUrl":"10.4022/jafib.20200439","url":null,"abstract":"<p><p>There is no consensus regarding optimal methodology forblood pressure monitoring inpatients with a depressed ejection fraction undergoingcatheter ablationfor atrial fibrillation. Our goalswere to determine ifhemodynamicmanagementdifferences exist during radiofrequency ablation for atrial fibrillation in patients with and without an ejection fraction< 50%, and whether management was influenced by the utilization of invasive arterial blood pressure monitoring. This single-center trial retrospectively compared blood pressure management during catheterablation of atrial fibrillationin all patients with an ejection fraction< 50% over a 2-year span (n=44), and compared to an age-matched cohort with preserved ejection fraction ablated over the same span in time (n=44). Blood pressure was not significantly managed differently between the groups, and did not appear to be influenced by the use of invasive arterial blood pressure monitoring.Hemodynamic management is similar across the spectrum of ejection fraction, regardless of invasive arterial blood pressure monitoring, which challenges the need for invasive arterial blood pressure monitoringduringcatheter ablation ofatrial fibrillationin left ventricular systolic dysfunction.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200439"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691288/pdf/jafib-13-20200439.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic, Clinical, and Angiographic Characteristics of Atrial Fibrillation Patients Suffering From de novo Acute Myocardial Infarction: A Subgroup Analysis of the MINOCA-TR Study Population.","authors":"Ali Coner, Cenk Ekmekci, Gokhan Aydin, Yasemin Kilavuz Dogan, Ozlem Arican Ozluk, Salih Kilic, Yunus Celik, Ismail Ungan, Mustafa Begenc Tascanov, Ramazan Duz, Veli Polat, Hakan Ozkan, Mehmet Ozyasar, Kamil Tuluce, Abdullah Icli, Devrim Kurt, Nurullah Cetin, Murat Gul, Sinan Inci, Mehdi Zoghi, Oktay Ergene, Ugur Onsel Turk","doi":"10.4022/jafib.20200468","DOIUrl":"10.4022/jafib.20200468","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) prevalence in patients with acute myocardial infarction (MI) ranges from 3% to 25%. However demographic, clinical, and angiographic characteristics of AF patients who admitted with de novo MI are unclear. The aim of this study was to investigate the prevalence of patients presenting with de novo MI with AF.</p><p><strong>Methods: </strong>The study was performed as a sub-study of the MINOCA-TR (Myocardial Infarction with Non-obstructive Coronary Arteries in Turkish Population) Registry, a multicenter, cross-sectional, observational, all-comer registry. MI patients without a known history of stable coronary artery disease and/or prior coronary revascularization were enrolled in the study. Patients were divided into AF and Non-AF groups according to presenting cardiac rhythm.</p><p><strong>Results: </strong>A total of 1793 patients were screened and 1626 were included in the study. The mean age was 61.5 (12.5) years. 70.7% of patients were men. The prevalence of AF was 3.1% (51 patients). AF patients were older [73.4 (9.4) vs. 61.0 (12.4) years, p<0.001] than non-AF patients. The proportion of women to men in the AF group was also higher than in the non-AF group (43.1% vs. 28.7%, p=0.027). Only 1 out of every 5 AF patients (10 patients, 19.6%) was using oral anticoagulants (OAC).</p><p><strong>Conclusions: </strong>AF prevalence in patients presenting with de novo MI was lower than previous studies that issued on AF prevalence in MI cohorts. The majority of AF patients did not have any knowledge of their arrhythmia and were not undergoing OAC therapy at admission, emphasizing the vital role of successful diagnostic strategies, patient education, and implementations for guideline adaptation.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200468"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691280/pdf/jafib-13-20200468.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Localization of Right Ventricular Outflow Tract Premature Ventricular Complexes Using a Novel Mapping System.","authors":"Mehmet Ali Elbey,&nbsp;Sri Harsha Kanuri,&nbsp;Naushad Shaikh,&nbsp;Rakesh Gopinathannair,&nbsp;Dhanunjaya Lakkireddy","doi":"10.4022/jafib.20200471","DOIUrl":"https://doi.org/10.4022/jafib.20200471","url":null,"abstract":"<p><p>Premature ventricular complexes (PVCs) are common in the general population, usuallyasymptomatic, and deemed to be benign in structurally normal hearts. The spectrum of \"benign\" outflow tract PVCs ranges from single PVCs to recurrent non-sustained ventricular tachycardia (NSVT). Short-coupled right ventricular outflow tract (RVOT) PVCs may trigger polymorphic ventricular tachycardia (VT) in some patients and can be high risk. In many patients, PVCs can be morefrequent and cause symptoms ofpalpitations, shortness of breath, dizziness, and heart failure.In the presence of underlying heart disease, they may indicate an increasedrisk of adverse cardiovascular outcomes. A high PVC burdenmay lead to ventricular dysfunction and worsen underlying cardiomyopathy.PVCs may also be a marker of underlying pathophysiologic processes such as myocarditisand other acquired and inherited infiltrative cardiomyopathies. In this unique case report, we describe the use of a novel non-contact mapping array for mapping RVOT PVCs.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200471"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691281/pdf/jafib-13-20200471.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate Control Versus Rhythm Control in Patients with Left Ventricular Assist Devices and Atrial Fibrillation.","authors":"Jasen L Gilge,&nbsp;Asim Ahmed,&nbsp;Bradley A Clark,&nbsp;Kathleen Morris,&nbsp;Zubin Yavar,&nbsp;Nicolas Beaudrie,&nbsp;Cameron Whitler,&nbsp;Mahera Husain,&nbsp;Mathew S Padanilam,&nbsp;Parin J Patel,&nbsp;Eric N Prystowsky,&nbsp;Ashwinn K Ravichandra","doi":"10.4022/jafib.20200474","DOIUrl":"https://doi.org/10.4022/jafib.20200474","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is a common comorbidity in patients with left ventricular assist devices (LVAD) with no defined guideline treatment strategy of rate versus rhythm control. The purpose of this study is to determine the effects of rate versus rhythm control for AF on the outcomes of patients with LVAD at our institution.</p><p><strong>Methods: </strong>Consecutive patients who underwent LVAD implantation at St Vincent Hospital from January 1, 2015 to December 31, 2017 were retrospectively evaluated. Patients with AF were identified and divided into rate control or rhythm control groups. The primary outcome evaluated was a composite of death, heart failure admission, gastrointestinal bleed, ventricular tachycardia, cerebrovascular accident, hemolysis, and pump thrombosis. Secondary outcomes included the individual variables from the primary outcome.</p><p><strong>Results: </strong>Out of 201 patients that underwent LVAD implantation, 81 had AF after implantation and were included with a median follow-up period of 384 days. The rate control group (n = 31; 38%) and the rhythm control group (n = 51; 62%) had no difference in composite outcomes (61% vs 59%, p = 0.83). When taken individually there was no difference in outcomes between the two groups. Thirteen patients underwent electrical cardioversion and successful conversion to normal sinus rhythm occurred in 71% of cases with a 60% recurrence rate.</p><p><strong>Conclusions: </strong>There was no difference in primary outcome between rate and rhythm control groups. These data suggest that maintenance of sinus rhythm may not be necessary in all patients with LVAD.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200474"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691283/pdf/jafib-13-20200474.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39871663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catheter Ablation for Persistent Atrial Fibrillation in Class IV Systolic Heart Failure: A Single-Center Case Series.","authors":"Aaron Hesselson,&nbsp;Heather Hesselson","doi":"10.4022/jafib.20200428","DOIUrl":"https://doi.org/10.4022/jafib.20200428","url":null,"abstract":"<p><p>Questions remain as to how aggressively catheter ablation for atrial fibrillation may be applied to patients with advanced systolic congestive heart failure, owing to a historic under-representation in multicenter clinical ablation trials. We sought to describe the experience of catheter ablation for persistent atrial fibrillation in Class IV systolic heart failure patients at our institution. All Class IV systolic heart failure patients (left ventricular assist device patients excluded) between 2017 and 2020 referred for radiofrequency ablation were included. Out of 10 patients, 7 agreed to proceed, had restoration of normal sinus rhythm upon completion of the catheter ablation procedure, and of which five (71%) remain in normal rhythm at a mean follow-up of 23 months. Catheter ablation for atrial fibrillation in patients with Class IV chronic systolic heart failure, even on advanced heart failure therapies, is feasible, and can improve heart failure status with maintenance of NSR.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 6","pages":"20200428"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691287/pdf/jafib-13-20200428.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39621008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}